Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 19, 2021Cardio-OncologyOpen Access

Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The rate of atrial arrhythmia in patients with pre-existing cardiovascular disease treated with ibrutinib was unknown.

Does pre-existing cardiovascular disease increase the risk of new-onset atrial fibrillation and mortality in patients with hematological malignancies treated with ibrutinib?

Population

217 ibrutinib-treated patients with no prior history of atrial arrhythmia

Comparison

Patients with pre-existing CVD vs those without CVD

Design

Single-institution retrospective chart review

Follow-up

Median of 1.1 years

Authors

JAJuan Carlo AvalonWest Virginia UniversityJFJacob FuquaWest Virginia UniversityTMTyler MillerWest Virginia University

Discussion

Loading...

Member takes

Overview

Supports arrhythmia risk stratification by CVD history in ibrutinib recipients; leaves open prospective validation and monitoring protocols.

Structured PICO

Does pre-existing cardiovascular disease increase the risk of new-onset atrial fibrillation and mortality in patients with hematological malignancies treated with ibrutinib?

P
Population
217 patients with hematological malignancies (72% CLL/SLL) with no prior history of atrial fibrillation, treated with ibrutinib. Median age 74, 64% male, 93% White. Single-institution retrospective cohort.
I
Intervention
Ibrutinib therapy in patients with pre-existing cardiovascular disease (known coronary artery disease, heart failure, pulmonary hypertension, pacemakers, implantable cardioverter defibrillators, ventricular arrhythmia, or at least moderate valvular heart disease).
C
Comparator
Ibrutinib therapy in patients without pre-existing cardiovascular disease.
O
Outcome
Incidence of new-onset atrial fibrillation after receiving ibrutinib.safety

In patients treated with ibrutinib for hematological malignancies, pre-existing cardiovascular disease nearly triples the odds of developing new-onset atrial fibrillation and significantly increases all-cause mortality.

Limitations

  • Small sample size
  • Retrospective design
  • Limited to single institutional EMR
  • Exact dates or timing of atrial fibrillation could not be located (time-to-event not possible)
  • Lack of echocardiographic variables (e.g., atrial size) for adjustment

Cite This Study

Avalon et al. (2021) studied this question.

synapsesocial.com/papers/6a70ab20febe604dd7097071https://doi.org/10.1186/s40959-021-00125-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ibrutinib for chronic graft-versus-host disease after failure of prior therapy2017 · 514 citations
  2. 2Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study2018 · 45 citations
  3. 3Hypertension and incident cardiovascular events following ibrutinib initiation2019 · 260 citations
  4. 4Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib2017 · 164 citations